Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

Dry skin, itching, and fiery eczema can be caused by allergens, stress, or an overactive immune response.Steroid creams ...

A successful five-year collaboration between Māori landowners, Manaaki Whenua–Landcare Research, Hā Kānuka (the Māori Kānuka ...

More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of ...

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.

Australia has the highest rates of childhood food allergy globally - 1 in 10 infants will have some sort of food allergy.

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...

All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

This NIHR Collection brings together major studies on the prevention and treatment of childhood eczema. It finds that many ...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...